A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjects - Hanes, Vladimir; Chow, Vincent; Stewart, Tina; Puri, Adeep (Cancer chemotherapy and pharmacology, 2021)
Keywords: Adult; Adverse events; Antibodies - blood; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - blood; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - immunology; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological products; Biosimilar Pharmaceuticals - administration & dosage; Biosimilar Pharmaceuticals - blood; Breast cancer; Cancer Research; Cancer therapies; Chemotherapy; Clinical trials; Dosage; Double-Blind Method; Double-blind studies; Drug dosages; Electrocardiography; Healthy Volunteers; Humans; Immunogenicity; Immunotherapy; Intravenous administration; Male; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Monoclonal antibodies; Oncology; Original; Original Article; Pharmacokinetics; Pharmacology; Pharmacology/Toxicology; Safety; Targeted cancer therapy; Trastuzumab; Trastuzumab - administration & dosage; Trastuzumab - blood; Trastuzumab - immunology; Biosimilars; Co-infusion; Pertuzumab; ABP 980; Safety; Pharmacokinetics; Trastuzumab